These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19188186)

  • 21. Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels.
    Xu X; Valtonen-André C; Sävblom C; Halldén C; Lilja H; Klein RJ
    Cancer Epidemiol Biomarkers Prev; 2010 Aug; 19(8):2035-42. PubMed ID: 20696662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Value of prostate-specific antigen density and transitional-zone prostate-specific antigen density in the diagnosis of prostate cancer].
    Martínez Jabaloyas JM; García Morata F; Villamón Fort R; Pastor Hernández F; Gil Salom M; García Sisamón F
    Actas Urol Esp; 2003 Jun; 27(6):442-9. PubMed ID: 12918151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
    Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
    Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels.
    Penney KL; Schumacher FR; Kraft P; Mucci LA; Sesso HD; Ma J; Niu Y; Cheong JK; Hunter DJ; Stampfer MJ; Hsu SI
    Carcinogenesis; 2011 Jun; 32(6):853-9. PubMed ID: 21421545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer.
    Mao Z; Ji A; Yang K; He W; Hu Y; Zhang Q; Zhang D; Xie L
    Medicine (Baltimore); 2018 Oct; 97(42):e12806. PubMed ID: 30334974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
    Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
    JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
    BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
    Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL.
    Ng CF; Chiu PK; Lam NY; Lam HC; Lee KW; Hou SS
    Int Urol Nephrol; 2014 Apr; 46(4):711-7. PubMed ID: 24136184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific antigen nomogram to predict advanced prostate cancer using area under the receiver operating characteristic curve boosting.
    Hashimoto T; Komori O; Nakashima J; Kashima T; Yamaguchi Y; Satake N; Nakagami Y; Shishido T; Namiki K; Ohno Y
    Urol Oncol; 2022 Apr; 40(4):162.e9-162.e16. PubMed ID: 35065881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome.
    Zhu Y; Ren S; Jing T; Cai X; Liu Y; Wang F; Zhang W; Shi X; Chen R; Shen J; Lu J; Xu C; Wang H; Wang H; Wang Y; Liu B; Li Y; Fang Z; Guo F; Qiao M; Shen D; Lu X; Gao X; Hou J; Sun Y
    Urol Oncol; 2015 Sep; 33(9):384.e9-20. PubMed ID: 26008593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease.
    Xu J; Isaacs SD; Sun J; Li G; Wiley KE; Zhu Y; Hsu FC; Wiklund F; Turner AR; Adams TS; Liu W; Trock BJ; Partin AW; Chang B; Walsh PC; Grönberg H; Isaacs W; Zheng S
    Clin Cancer Res; 2008 Sep; 14(18):5819-24. PubMed ID: 18794092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer.
    Chang BL; Hughes L; Chen DY; Gross L; Ruth K; Giri VN
    BJU Int; 2014 May; 113(5b):E150-6. PubMed ID: 23937305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening.
    Jen HH; Chang WJ; Hsu CY; Yen AM; Auvinen A; Chen TH; Chen SL
    Sci Rep; 2020 Nov; 10(1):20665. PubMed ID: 33244038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of percent free prostate-specific antigen density to improve the specificity for detecting prostate cancer in patients with normal rectal examinations and intermediate prostate-specific antigen levels.
    Baltaci S; Aksoy H; Türkölmez K; Elhan AH; Ozden E; Göğüş O
    Urol Int; 2003; 70(1):36-41. PubMed ID: 12566813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PSA velocity and PSA slope.
    Benecchi L
    Prostate Cancer Prostatic Dis; 2006; 9(2):169-72. PubMed ID: 16568147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium.
    Song ZJ; Qian JK; Yang Y; Wu HX; Wang MY; Jiang SY; Wang FB; Zhang W; Chen R;
    Asian J Androl; 2021; 23(3):300-305. PubMed ID: 33208562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.
    Preston MA; Batista JL; Wilson KM; Carlsson SV; Gerke T; Sjoberg DD; Dahl DM; Sesso HD; Feldman AS; Gann PH; Kibel AS; Vickers AJ; Mucci LA
    J Clin Oncol; 2016 Aug; 34(23):2705-11. PubMed ID: 27298404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA).
    Ceriani L; Giovanella L; Salvadore M; Bono AV; Roncari G
    Int J Biol Markers; 1997; 12(1):27-34. PubMed ID: 9176715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.